RESUMEN
Background and objective: Severe metabolic complications generally manifest at an early age in Berardinelli - Seip congenital lipodystrophy (BSCL) and their management is especially challenging. Nutritional intervention with low lipid diets is considered by experts to be fundamental in treating the disease when associated with medical therapy, however little is known about the beneficial effects of dietary interventions alone. Aim: To underline the importance of a well-structured low-fat diet in BSCL patients. Methods and results: A BSCL male patient strictly followed a hypocaloric hypolipemic diet (60% carbohydrates, 22% fats and 18% proteins) since clinical diagnosis at the age of one year. Interestingly, pharmacological interventions were not required at any point during the follow-up. Aged 16 years the patient was referred to our center. Biochemistry, hormonal evaluation, 75 mg oral glucose tolerance test, cardiac evaluation and abdominal ultrasound were performed, revealing no abnormalities. Genetic analysis and leptin dosage were carried out, confirming the diagnosis of BSCL type 1 (homozygosity for c.493-1G>C pathogenic variant in AGPAT2 gene) and showing undetectable circulating levels of leptin (< 0.2 mcg/L). Diet therapy alone was therefore maintained, scheduling follow-up visits every six months, with acceptable disease control ever since. Conclusions: This report proves how a low-fat diet is of great help in the management of BSCL and its complications. In addition, a specific hypolipemic diet could be used alone as an effective treatment in selected cases with high compliance and, probably, a milder phenotype.
Asunto(s)
Leptina , Lipodistrofia Generalizada Congénita , Masculino , Humanos , Leptina/genética , Lipodistrofia Generalizada Congénita/genética , Lipodistrofia Generalizada Congénita/terapia , Fenotipo , Dieta con Restricción de Grasas , HomocigotoRESUMEN
Berardinelli Seip Syndrome is a rare disorder associated with loss of adipose tissue leading to a myriad of findings owing to derangements of carbohydrate and lipid metabolism. There is no cure and the management comprising low fat diet, metformin and leptin replacement is aimed at preventing complications. We report this syndrome in a male child from Afghanistan.
Asunto(s)
Dieta con Restricción de Grasas , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/terapia , Preescolar , Hepatomegalia/etiología , Humanos , Hipoglucemiantes/uso terapéutico , Leptina/uso terapéutico , Lipodistrofia Generalizada Congénita/complicaciones , Masculino , Metformina/uso terapéuticoRESUMEN
Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications. Here, we describe a 10-year-old girl with genetically proven Berardinelli Seip congenital generalized lipodystrophy type 2, diagnosed at 10 months of age. She developed comorbidities like proteinuria, hypertension, diabetes mellitus, and liver fibrosis.
Asunto(s)
Predisposición Genética a la Enfermedad , Hipertensión/diagnóstico , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/terapia , Niño , Diabetes Mellitus/fisiopatología , Progresión de la Enfermedad , Femenino , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , India , Resistencia a la Insulina , Lipodistrofia Generalizada Congénita/genética , Cirrosis Hepática/complicaciones , Cirrosis Hepática/fisiopatología , Enfermedades Raras , Índice de Severidad de la EnfermedadRESUMEN
Berardinelli-Seip syndrome, or congenital generalized lipodystrophy type 2 (CGL2), is characterized by a lack of subcutaneous adipose tissue and precocious metabolic syndrome with insulin resistance, resulting in diabetes, dyslipidaemia, hepatic steatosis, cardiomyopathy, and acanthosis nigricans. Most reported mutations are associated with mild, non-progressive neurological impairment. We describe the clinical and EEG data of a patient with progressive myoclonus epilepsy (PME), CGL2, and progressive neurological impairment, carrying a homozygous BSCL2 nonsense mutation. The patient had epilepsy onset at the age of two, characterized by monthly generalized tonic-clonic seizures. By the age of three, he presented with drug-resistant ongoing myoclonic absence seizures, photosensitivity, progressive neurological degeneration, and moderate cognitive delay. Molecular analysis of the BSCL2 gene yielded a homozygous c.(1076dupC) p.(Glu360*) mutation. Application of a vagus nerve stimulator led to temporary improvement in seizure frequency, general neurological condition, and EEG background activity. Specific BSCL2 mutations may lead to a peculiar CGL2 phenotype characterized by PME and progressive neurodegeneration. Application of a vagus nerve stimulator, rarely used for PMEs, may prove beneficial, if only temporarily, for both seizure frequency and general neurological condition.
Asunto(s)
Subunidades gamma de la Proteína de Unión al GTP/genética , Lipodistrofia Generalizada Congénita , Epilepsias Mioclónicas Progresivas , Preescolar , Electroencefalografía , Humanos , Lipodistrofia Generalizada Congénita/genética , Lipodistrofia Generalizada Congénita/fisiopatología , Lipodistrofia Generalizada Congénita/terapia , Masculino , Epilepsias Mioclónicas Progresivas/genética , Epilepsias Mioclónicas Progresivas/fisiopatología , Epilepsias Mioclónicas Progresivas/terapia , Estimulación del Nervio VagoRESUMEN
Lipodystrophy is a heterogeneous group of disorders characterized by loss of adipose tissue. Here, we report on clinical spectra of neuromuscular manifestations of Turkish patients with lipodystrophy. Seventy-four patients with lipodystrophy and 20 healthy controls were included. Peripheral sensorimotor neuropathy was a common finding (67.4%) in lipodystrophic patients with diabetes. Neuropathic foot ulcers were observed in 4 patients. Drop foot developed in 1 patient with congenital generalized lipodystrophy type 1. Muscle symptoms and hypertrophy were consistent findings in congenital generalized lipodystrophy (21/21) and familial partial lipodystrophy (25/34); on the other hand, overt myopathy with elevated creatine kinase activity was a distinctive characteristic of congenital generalized lipodystrophy type 4. Muscle biopsies revealed myopathic changes at different levels. Accumulation of triglycerides was observed which contributes to insulin resistance. All patients with congenital generalized lipodystrophy suffered from tight Achilles tendons at various levels. Scoliosis was observed in congenital generalized lipodystrophy type 4 (2/2) and familial partial lipodystrophy type 2 (2/17). Atlantoaxial instability was unique to congenital generalized lipodystrophy type 4 (2/2). Bone cysts were detected in congenital generalized lipodystrophy type 1 (7/10) and congenital generalized lipodystrophy type 2 (2/8). Our study suggests that lipodystrophies are associated with a wide spectrum of neuromuscular abnormalities.
Asunto(s)
Tejido Adiposo/patología , Lipodistrofia Generalizada Congénita/patología , Lipodistrofia Parcial Familiar/patología , Enfermedades Musculares/patología , Adolescente , Adulto , Femenino , Humanos , Resistencia a la Insulina/fisiología , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/terapia , Lipodistrofia Parcial Familiar/diagnóstico , Lipodistrofia Parcial Familiar/terapia , Masculino , Persona de Mediana Edad , Músculos/patología , Triglicéridos/metabolismo , Adulto JovenRESUMEN
CONTEXT: Lipodystrophy syndromes are characterized by generalized or partial absence of adipose tissue. OBJECTIVE: We conducted a systematic review to synthesize data on clinical and metabolic features of lipodystrophy (age at onset, < 18 years). DATA SOURCE: Sources included Medline, Embase, Cochrane Library, Scopus and Non-Indexed Citations from inception through January 2016. STUDY SELECTION: Search terms included lipodystrophy, and age 0 to 18 years. Patients with unambiguous diagnosis of lipodystrophy were included. Lipodystrophy secondary to HIV treatment was excluded. DATA SYNTHESIS: We identified 1141 patients from 351 studies. Generalized fat loss involving face, neck, abdomen, thorax, and upper and lower limbs was explicitly reported in 65% to 93% of patients with congenital generalized lipodystrophy (CGL) and acquired generalized lipodystrophy (AGL). In familial partial lipodystrophy (FPL), fat loss occurred from upper and lower limbs, with sparing of face and neck. In acquired partial lipodystrophy (APL), upper limbs were involved while lower limbs were spared. Other features were prominent musculature, acromegaloid, acanthosis nigricans and hepatosplenomegaly. Diabetes mellitus was diagnosed in 48% (n = 222) of patients with CGL (mean age at onset, 5.3 years). Hypertriglyceridemia was observed in CGL, AGL and FPL. Multiple interventions were used, with most patients receiving ≥ 3 interventions and being ≥ 18 years of age at the initiation of interventions. CONCLUSIONS: To our knowledge, this is the largest reported pooled database describing lipodystrophy patients with age at onset < 18 years. We have suggested core and supportive clinical features and summarized data on available interventions, outcomes and mortality.
Asunto(s)
Lipodistrofia/diagnóstico , Niño , Síndrome de Lipodistrofia Asociada a VIH , Humanos , Lipodistrofia/mortalidad , Lipodistrofia/terapia , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/mortalidad , Lipodistrofia Generalizada Congénita/terapiaRESUMEN
Congenital generalized lipodystrophy type 4 is an extremely rare autosomal recessive disorder. We report our clinical experience on two unrelated Turkish patients with congenital generalized lipodystrophy type 4. A 13-year-old girl (patient-1) presented with generalized lipodystrophy and myopathy. Further tests revealed ventricular and supraventricular arrhythmias, gastrointestinal dysmotility, atlantoaxial instability, lumbosacral scoliosis, and metabolic abnormalities associated with insulin resistance. A 16-year-old girl (patient-2) with congenital generalized lipodystrophy type 4 was previously reported. Here, we report on her long term clinical follow-up. She received several course of anti-arrhythmic treatments for catecholaminergic polymorphic ventricular tachycardia and rapid atrial fibrillation. An implantable cardioverter defibrillator was also placed. A homozygous PTRF mutation, c.259C > T (p.Gln87*), was identified in patient-1. Congenital generalized lipodystrophy type 4 was caused by homozygous PTRF c.481-482insGTGA (p.Lys161Serfs*41) mutation in patient-2. Our data indicate that patients with congenital generalized lipodystrophy type 4 should be meticulously evaluated for cardiac, neuromuscular, gastrointestinal and skeletal diseases, as well as metabolic abnormalities associated with insulin resistance.
Asunto(s)
Arritmias Cardíacas/genética , Resistencia a la Insulina/genética , Lipodistrofia Generalizada Congénita/genética , Proteínas de Unión al ARN/genética , Adolescente , Arritmias Cardíacas/fisiopatología , Arritmias Cardíacas/terapia , Femenino , Homocigoto , Humanos , Lipodistrofia Generalizada Congénita/fisiopatología , Lipodistrofia Generalizada Congénita/terapia , Mutación , Linaje , Taquicardia Ventricular/genética , Taquicardia Ventricular/fisiopatología , Taquicardia Ventricular/terapia , TurquíaRESUMEN
Congenital generalized lipodystrophy (CGL) is a heterogeneous autosomal recessive disorder characterized by a near complete lack of adipose tissue from birth and, later in life, the development of metabolic complications, such as diabetes mellitus, hypertriglyceridaemia and hepatic steatosis. Four distinct subtypes of CGL exist: type 1 is associated with AGPAT2 mutations; type 2 is associated with BSCL2 mutations; type 3 is associated with CAV1 mutations; and type 4 is associated with PTRF mutations. The products of these genes have crucial roles in phospholipid and triglyceride synthesis, as well as in the formation of lipid droplets and caveolae within adipocytes. The predominant cause of metabolic complications in CGL is excess triglyceride accumulation in the liver and skeletal muscle owing to the inability to store triglycerides in adipose tissue. Profound hypoleptinaemia further exacerbates metabolic derangements by inducing a voracious appetite. Patients require psychological support, a low-fat diet, increased physical activity and cosmetic surgery. Aside from conventional therapy for hyperlipidaemia and diabetes mellitus, metreleptin replacement therapy can dramatically improve metabolic complications in patients with CGL. In this Review, we discuss the molecular genetic basis of CGL, the pathogenesis of the disease's metabolic complications and therapeutic options for patients with CGL.
Asunto(s)
Lipodistrofia Generalizada Congénita/metabolismo , Tejido Adiposo/metabolismo , Humanos , Lipodistrofia Generalizada Congénita/genética , Lipodistrofia Generalizada Congénita/terapiaRESUMEN
Congenital lipodystrophies are heterogeneous genetic diseases, leading to the loss of adipose tissue. This loss of adipose tissue can be generalized or partial, thus defining different phenotypes. These lipodystrophies have a major metabolic impact, secondary to lipotoxicity. This lipotoxicity is responsible for insulin resistance, dyslipidemia and hepatic steatosis. The severity of the metabolic impact correlates with the severity of the loss of adipose tissue. Mutations in 15 predisposition genes are currently described; BSCL2 and AGPT2 genes are the major genes in the generalized forms. On the contrary, LMNA and PPARG gene mutations are recovered in partial lipodystrophies forms. These different genes encode for proteins involved in adipocyte physiology, altering adipocyte differentiation, triglycerides synthesis and lysis or playing a major role in the lipid droplet formation. Congenital lipodystrophies treatment is based on the management of metabolic comorbidities but recombinant leptin therapy appears to have promising results. These different points have been recently discussed during the 2015 Endocrine Society Congress, notably by S. O'Rahilly and are highlighted in this review.
Asunto(s)
Lipodistrofia Generalizada Congénita/genética , Lipodistrofia/congénito , Lipodistrofia/genética , Adipocitos/fisiología , Tejido Adiposo/patología , Adolescente , Adulto , Angiopoyetina 2/genética , Femenino , Subunidades gamma de la Proteína de Unión al GTP/genética , Predisposición Genética a la Enfermedad , Humanos , Lamina Tipo A/genética , Leptina/uso terapéutico , Lipodistrofia/terapia , Lipodistrofia Generalizada Congénita/patología , Lipodistrofia Generalizada Congénita/terapia , Mutación , PPAR gamma/genética , Proteínas RecombinantesRESUMEN
Berardinelli-Seip congenital lipodystrophy (BSCL) syndrome is a rare autosomal-recessive disease characterised by lipoatrophy and associated with deregulations of glycidic and lipid metabolism. We report three BSCL cases with its typical clinical picture and complications. Clinically, they all show marked atrophy of adipose tissue, acromegaly, acanthosis nigricans and tall stature. Two cases present attention deficit hyperactivity and developmental learning disorders; another patient has hypertrophic myocardiopathy and polycystic ovary syndrome. In all the cases AGPAT2 was the identified mutation. All the cases present hypertriglyceridemia. One case has developed hyperinsulinism controlled with metformin and another case already has type 2 diabetes with a difficult clinical control. There is no curative treatment and the current treatment options are based only on symptomatic control of the complications. Recently, published studies showed that leptin-replacement therapy appears a promising tool in the metabolic correction of BSCL complications, highlighting the importance of further investigations in BSCL treatment.
Asunto(s)
Lipodistrofia Generalizada Congénita/terapia , Acantosis Nigricans/etiología , Acromegalia/etiología , Aciltransferasas/genética , Niño , Femenino , Humanos , Hiperinsulinismo/etiología , Hipertrigliceridemia/etiología , Lipodistrofia Generalizada Congénita/complicaciones , Lipodistrofia Generalizada Congénita/genética , Masculino , Linaje , Adulto JovenRESUMEN
Berardinelli- Seip syndrome is an autosomal recessive disorder characterized by generalized lipoatrophy, extreme insulin resistance with dyslipidemia in childhood and development of diabetes in adolescence. Menstrual irregularities are commonly seen as a result of secondary polycystic ovarian syndrome. Delayed puberty as a manifestation of these abnormalities in girls has rarely been described earlier. We report one such case patient who had delayed puberty and portal hypertension as unique features amongst the characteristic phenotypes of this syndrome.
Asunto(s)
Hipertrigliceridemia/diagnóstico , Lipodistrofia Generalizada Congénita/diagnóstico , Pubertad Tardía/diagnóstico , Administración Cutánea , Adolescente , Atorvastatina , Terapia Combinada , Dieta con Restricción de Grasas , Quimioterapia Combinada , Estrógenos/administración & dosificación , Estrógenos/uso terapéutico , Terapia por Ejercicio , Femenino , Fenofibrato/uso terapéutico , Aceites de Pescado/administración & dosificación , Ácidos Heptanoicos/uso terapéutico , Humanos , Hipertensión Portal/sangre , Hipertensión Portal/diagnóstico , Hipertensión Portal/tratamiento farmacológico , Hipertrigliceridemia/sangre , Insulina/uso terapéutico , Resistencia a la Insulina/fisiología , Lipodistrofia Generalizada Congénita/sangre , Lipodistrofia Generalizada Congénita/terapia , Pioglitazona , Propranolol/uso terapéutico , Pubertad Tardía/sangre , Pirroles/uso terapéutico , Tiazolidinedionas/uso terapéutico , Resultado del TratamientoRESUMEN
CONTEXT: Recently, in a 4-month proof-of-concept trial, beneficial metabolic effects were reported in non-diabetic children with Berardinelli-Seip congenital lipodystrophy (BSCL); this information prompted us to hypothesize that long-term leptin-replacement therapy might improve or reverse the early complications of the disease in these patients. PATIENTS AND METHODS: A 28-month trial was implemented in eight patients. Efficacy assessment was based on a decrease in serum triglyceride concentrations, and/or a decrease in liver volume and/or an increase in insulin sensitivity of at least 30% respectively. The response was defined as follows: total (3/3 positive criteria), partial (1 or 2/3), or negative (0/3). Anti-leptin antibodies were measured with a radiobinding assay, and a neutralizing effect was assessed in primary cultures of embryonic neurons incubated with an apoptotic agent (N-methyl-D-aspartate) and the patient serum, with or without leptin. RESULTS: A negative or partial response to treatment was observed in five of eight patients even when leptin dosages were increased. A displaceable leptin binding was detectable in all patients after 2 months of treatment. At 28 months, binding was higher in the patients with a negative response than in the total responders, and it paralleled both the increase in leptin dosage and serum leptin concentrations. Co-incubation of embryonic neurons with serum from two patients with a negative response inhibited the neuroprotective effect of leptin. CONCLUSION: Under leptin therapy, patients with BSCL may develop a resistance to leptin, which could be partly of immunological origin, blunting the previously reported beneficial effects.
Asunto(s)
Anticuerpos Neutralizantes/inmunología , Leptina/administración & dosificación , Lipodistrofia Generalizada Congénita/inmunología , Adolescente , Anticuerpos Neutralizantes/metabolismo , Glucemia/metabolismo , Composición Corporal , Niño , Preescolar , Esquema de Medicación , Femenino , Humanos , Leptina/metabolismo , Metabolismo de los Lípidos , Lípidos/sangre , Lipodistrofia Generalizada Congénita/metabolismo , Lipodistrofia Generalizada Congénita/terapia , Hígado/metabolismo , Masculino , Selección de Paciente , Estudios Prospectivos , Estadísticas no Paramétricas , Resultado del TratamientoRESUMEN
Congenital Generalized Lipodystrophy (CGL) or Berardinelli-Seip Syndrome (BSCL) is a rare autosomal recessive disease characterized by complete absence of adipose tissue and by several metabolic alterations in carbohydrate (diabetes mellitus) and lipid metabolism and involvement of heart, bone and ovaries. Mental retardation and psychiatric disturbances are present in a variable proportion of affected patients. In the present review, the major advances in clinical, molecular and genetic characterization of BSCL affected subjects are recorded and discussed.
Asunto(s)
Tejido Adiposo/metabolismo , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/metabolismo , Brasil/epidemiología , Genotipo , Humanos , Lipodistrofia Generalizada Congénita/genética , Lipodistrofia Generalizada Congénita/terapia , FenotipoRESUMEN
Congenital generalized lipodystrophy (CGL) is a rare disorder characterized by near complete absence of adipose tissue from birth. At least 2 genes located in 9q34 (AGPAT2) and 11q13 (Seipin) are implicated in type 1 and 2, respectively, and result in insulin resistance. We report here a novel case of CGL type 1 resulting from a novel homozygote mutation in the AGPAT2 gene. The clinical picture included pseudoathletic muscular hypertrophy, hypertrophic cardiomyopathy, enlarged liver, hypermetabolism rate, and hyperinsulinemia in a 1-year-old child from Libya. Peripheral hypertonia and reflex excitability revealed signal abnormalities in white matter on magnetic resonance imagery, which has not been described previously in the literature.
Asunto(s)
Lipodistrofia Generalizada Congénita , Adolescente , Factores de Edad , Encefalopatías/diagnóstico , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Genotipo , Homocigoto , Humanos , Lactante , Recién Nacido , Resistencia a la Insulina , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/genética , Lipodistrofia Generalizada Congénita/fisiopatología , Lipodistrofia Generalizada Congénita/terapia , Imagen por Resonancia Magnética , Mutación , Fenotipo , Factores de Tiempo , Resultado del TratamientoRESUMEN
Lipoatrophy syndromes are characterized by an absence of adipose tissue and low leptin levels. Metabolic derangements associated with these syndromes can include diabetes mellitus, insulin resistance, and hyperlipidemia.
Asunto(s)
Diabetes Mellitus Lipoatrófica/diagnóstico , Diabetes Mellitus Lipoatrófica/metabolismo , Lipodistrofia Generalizada Congénita/diagnóstico , Lipodistrofia Generalizada Congénita/metabolismo , Adolescente , Negro o Afroamericano , Diabetes Mellitus Lipoatrófica/tratamiento farmacológico , Femenino , Humanos , Lipodistrofia Generalizada Congénita/terapiaRESUMEN
Congenital generalized lipodystrophy, also known as Berardinelli-Seip syndrome, is a very rare hereditary syndrome that is characterized by an almost complete absence of adipose tissue from birth. Cardiac involvement seems to have substantial influence in the long-term prognosis. Herein, we report an apparently unique case of congenital generalized lipodystrophy with cardiac sequelae. A 17-year-old woman, diagnosed in childhood with Berardinelli-Seip syndrome, presented with severe epigastric pain that was secondary to previous myocardial infarction. The patient had ischemia, dilated cardiomyopathy, and congestive heart failure, but no coronary artery disease. She was discharged from the hospital in stable condition after 3 days of medical treatment. To our knowledge, this is the 1st reported case of congenital generalized lipodystrophy with dilated cardiomyopathy, congestive heart failure, severe mitral regurgitation, and inferior myocardial infarction as cardiac sequelae of this syndrome--but without evidence of coronary artery disease or cardiac hypertrophy. In addition to discussing this patient's case, we present diagnostic and therapeutic approaches to Berardinelli-Seip syndrome.